AU2022248775A1 - Nanogel-coated vaccine - Google Patents

Nanogel-coated vaccine Download PDF

Info

Publication number
AU2022248775A1
AU2022248775A1 AU2022248775A AU2022248775A AU2022248775A1 AU 2022248775 A1 AU2022248775 A1 AU 2022248775A1 AU 2022248775 A AU2022248775 A AU 2022248775A AU 2022248775 A AU2022248775 A AU 2022248775A AU 2022248775 A1 AU2022248775 A1 AU 2022248775A1
Authority
AU
Australia
Prior art keywords
nanogel
vlp
pro
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022248775A
Other languages
English (en)
Inventor
Hiroshi Kiyono
Yoshikazu Yuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanavax Inc
University of Tokyo NUC
Original Assignee
Hanavax Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanavax Inc, University of Tokyo NUC filed Critical Hanavax Inc
Publication of AU2022248775A1 publication Critical patent/AU2022248775A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022248775A 2021-03-30 2022-03-28 Nanogel-coated vaccine Pending AU2022248775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021056392 2021-03-30
JP2021-056392 2021-03-30
PCT/JP2022/014798 WO2022210465A1 (ja) 2021-03-30 2022-03-28 ナノゲル被覆型ワクチン

Publications (1)

Publication Number Publication Date
AU2022248775A1 true AU2022248775A1 (en) 2023-10-12

Family

ID=83459198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022248775A Pending AU2022248775A1 (en) 2021-03-30 2022-03-28 Nanogel-coated vaccine

Country Status (8)

Country Link
US (1) US20240181033A1 (https=)
EP (1) EP4316511A4 (https=)
JP (1) JPWO2022210465A1 (https=)
KR (1) KR20230163443A (https=)
CN (1) CN117098549A (https=)
AU (1) AU2022248775A1 (https=)
CA (1) CA3212267A1 (https=)
WO (1) WO2022210465A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566516B1 (en) 1998-08-31 2003-05-20 Nof Corporation High purity polysaccharide containing a hydrophobic group and process for producing it
JP5344558B2 (ja) 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
JP2020019754A (ja) * 2018-08-03 2020-02-06 国立研究開発法人農業・食品産業技術総合研究機構 ウシ乳房炎に対する粘膜ワクチン組成物

Also Published As

Publication number Publication date
US20240181033A1 (en) 2024-06-06
CN117098549A (zh) 2023-11-21
JPWO2022210465A1 (https=) 2022-10-06
CA3212267A1 (en) 2022-10-06
KR20230163443A (ko) 2023-11-30
WO2022210465A1 (ja) 2022-10-06
EP4316511A1 (en) 2024-02-07
EP4316511A4 (en) 2025-05-21

Similar Documents

Publication Publication Date Title
AU2021228098B2 (en) Soluble ACE2 and fusion protein, and applications thereof
AU2016379413B2 (en) Covalent polymer-antigen conjugated particles
JP5344558B2 (ja) カチオン性ナノゲルを用いる粘膜ワクチン
AU2020411873B2 (en) Mutant RSV F protein and use thereof
AU2021225827B2 (en) Humanized monoclonal antibody for 2019 novel coronavirus and use thereof
KR20210035752A (ko) 항-바이러스 활성이 향상된 나노천공자
EP1666059A1 (en) Novel vaccine containing adjuvant capable of inducing mucosal immunity
HUP0001838A2 (hu) Anyagok nyálkahártyán át történő beadása emlősöknek
AU2020366472B2 (en) Carrier protein with site-directed mutation and use thereof in preparation of vaccine
US12453768B2 (en) Vaccines for in vivo expression of nucleic acids and methods of using the same
AU2022207569A9 (en) Stable preparation of human papillomavirus virus-like particle vaccine
CN113456810A (zh) 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用
Upadhyay et al. Recent advancement in SARS-CoV-2 diagnosis, treatment, and vaccine formulation: a new paradigm of nanotechnology in strategic combating of COVID-19 pandemic
CA2121559C (en) Immunogenic artificial polypeptide
US9833407B2 (en) Nasal vaccine for Streptococcus pneumoniae
US20200306364A1 (en) Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
JP2013515490A (ja) 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護
AU2022248775A1 (en) Nanogel-coated vaccine
US20230038487A1 (en) Modified viral therapeutics and uses thereof
Panigrahi et al. Nanotheranostics and its role in diagnosis, treatment and prevention of COVID-19
Taghizadeh et al. Nasal administration of M2e/CpG-ODN encapsulated in n-trimethyl chitosan (TMC) significantly increases specific immune responses in a mouse model
AU2020285291B2 (en) M1 virus mutant and use thereof
CA2429144A1 (fr) Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur ou adjuvant
US11298415B2 (en) Alginate chitosan nanoformulation of OmpA—a Shigella protein subunit
Thakur et al. COVID detection via nanotechnology: a promising field in the diagnosis and analysis of novel coronavirus infection